Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
3.480
-0.250 (-6.70%)
At close: Dec 5, 2025, 4:00 PM EST
3.540
+0.060 (1.72%)
After-hours: Dec 5, 2025, 7:59 PM EST
Ironwood Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Ironwood Pharmaceuticals stock have an average target of 5.34, with a low estimate of 0.70 and a high estimate of 14. The average target predicts an increase of 53.45% from the current stock price of 3.48.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ironwood Pharmaceuticals stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $1 → $3 | Hold | Maintains | $1 → $3 | -13.79% | Nov 11, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $7 → $1 | Buy → Hold | Downgrades | $7 → $1 | -71.26% | Apr 15, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $8 → $0.7 | Strong Buy → Hold | Downgrades | $8 → $0.7 | -79.89% | Apr 15, 2025 |
| Leerink Partners | Leerink Partners | Hold Maintains $3 → $1 | Hold | Maintains | $3 → $1 | -71.26% | Apr 14, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $23 → $14 | Buy | Maintains | $23 → $14 | +302.30% | Jan 30, 2025 |
Financial Forecast
Revenue This Year
313.24M
from 351.41M
Decreased by -10.86%
Revenue Next Year
325.79M
from 313.24M
Increased by 4.01%
EPS This Year
0.30
from 0.01
Increased by 5,340.25%
EPS Next Year
0.49
from 0.30
Increased by 64.41%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 324.6M | 350.7M | ||||
| Avg | 313.2M | 325.8M | ||||
| Low | 299.9M | 304.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -7.6% | 12.0% | ||||
| Avg | -10.9% | 4.0% | ||||
| Low | -14.7% | -2.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.34 | 0.53 | ||||
| Avg | 0.30 | 0.49 | ||||
| Low | 0.26 | 0.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 5,974.9% | 74.5% | ||||
| Avg | 5,340.2% | 64.4% | ||||
| Low | 4,683.9% | 53.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.